The Potential Investment Impact of Improved Access to Accelerated Approval on the Development of Treatments for Low Prevalence Rare Diseases

July 06, 2011

Share this page

Research brings attention to the need for well-defined and practical qualification criteria for the use of surrogate endpoints to allow more access to the AA approval pathway in clinical trials for rare diseases.

Accelerated Approval

Related Articles

FDA Rare Disease Roundtable – June 3, 2026 June 04, 2026
Rare Disease Community Wins Victory Over Oregon's Harmful Accelerated Approval Proposal September 28, 2022
EveryLife Issues Statement on House Energy & Commerce Hearing March 17, 2022